View Older Stories View More Recent Stories
-
Motorcar Parts of America, Inc. (MPAA) to Offer 2M Shares
-
Roth Capital Downgrades RGS Energy (RGSE) to Neutral
-
Roth Affirms Cytori (CYTX) at Buy Following BARDA Update
-
Daqo New Energy (DQ) Could Win with New China PV Ban; Canadian Solar (CSIQ), Trina (TSL) Others on Losing End - Roth Capital
-
Roth Lifts PT on Plug Power (PLUG) Following Q2 Results; Highlights Key Takeaways from the Quarter
-
Roth Remains Positive on Ligand Pharma (LNGD) Following New Licensing Agreement with Avion Pharma
-
Roth Affirms Rexahn (RNN) at 'Buy'; Comments on Q2 Results, Pipeline Update
-
Roth Capital Encouraged by ReneSola's (SOL) Progress, but Sustainable Profits Need to be Demonstrated
-
Roth Keeps Concert Pharma (CNCE) at Buy; Making Good Progress with Clinical Programs
-
Roth Capital Affirms 'Sell' Rating on Dendreon (DNDN) Following Q2 Results; Comments on Debt Issue
-
UTStarcom (UTSI) CFO Resigns, Replacement Named
-
Energy Focus Closes Public Offering of Common Stock
-
Roth Capital Comments on Regeneron (REGN) After EC Approves Eylea for DME Patients
-
Roth Capital Starts IRadimed Corp (IRMD) at Buy
-
Roth Capital Raises Target on SolarCity (SCTY) 22.5% Following Q2 Results
-
Roth Capital Downgrades Alexza Pharma (ALXA) to Neutral
-
Roth Maintains Keryx (KERX) at 'Buy' Following Q2 Results; Long-Term Study Data Still Looks Good
-
Roth Capital Upgrades PowerSecure (POWR) to Buy
-
New CEO Whitaker is Positive for Synta Pharma (SNTA); Roth Affirms at 'Buy' Following Q2 Results
-
Roth Raises Target on Enphase (ENPH) 50% Following Q2 Results and Outlook
-
Energy Focus Announces Pricing of Public Offering of Common Stock
-
Roth Capital Comments on Regeneron (REGN) Following Q2 Results; Affirms 'Buy' Rating
-
Roth Still Positive on Ligand (LGND) Following Q2 Results, ASPIRE Phase 3 Update (AMGN)
-
Key Takeaways from Hydrogenics' (HYGS) Q2 Report
-
AGTC Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Roth Capital Starts Sucampo Pharmaceuticals (SCMP) at Buy
-
Roth Capital Starts Alcobra Ltd. (ADHD) at Buy
-
Cytokinetics (CYTK) Valuation Remains Attractive Following Q2 Results - Roth
-
Streetinsider.com's Hot Lunchtime Reads 07/31:(NQ) (TMUS) (TSLA) (AMCX) (MCUR)
-
New CEO Encouraging, but Plenty of Problems Persist at Dendreon (DNDN) - Roth Capital
-
Bio Blast Pharma (ORPN) IPO Opens, Trades Lower
-
Maxwell (MXWL) Risk-Reward Favorable into Q2 Report on Recent Pullback, FY15 Bus Read Through
-
Roth Boosts PT on Regeneron (REGN) to $399 Following ODYSSEY Phase III Data, EYLEA Approval
-
Roth Capital Comments on Pharmacyclics (PCYC) Following Expanded IMBRUVICA Coverage; Affirms 'Buy' Rating
-
Roth Affirms 'Buy' Rating on Stemline (STML); Comments on SL-401 News
-
Pre-Open Stock Movers 7/28: (FDO) (XGTI) (TRLA) Higher; (ACRX) (HZNP) (Z) Lower (more...)
-
Roth Capital Upgrades Prosensa (RNA) to Buy
-
Roth Highlights Two Takeaways from SolarCity's (SCTY) ABS Offering; Maintains 'Buy' Rating
-
Mines Management (MGN) Plans 4,000 Units Offering
-
Roth Positive on Pharmacyclics (PCYC) Following CHMP Recommendation of Imbruvica
-
Applied Genetic Technologies (AGTC) Prices 2M Common Offering at $15/Share
-
AGTC Announces Pricing of Public Offering
-
Notable Analyst Rating Changes 07/24: (RKUS) (UIS) (SEIC) Upgraded; (ANGI) (QCOM) (BA) Downgraded
-
Roth Capital Starts CorMedix (CRMD) at Buy
-
Roth Sees Significant Advantages to TG Therapeutics' (TGTX) TGR-1202 vs. Gilead's (GILD) Zydelig; Reiterates 'Focus Pick' Rating
-
Ligand (LGND) Pressure on GSK's Promacta Data is Overreaction - Roth Capital
-
NHLBI Trial Choice Validates Cytori (CYTX) as Top Stem Cell Player - Roth Capital
-
Notable Analyst Rating Changes 07/22: (AGN) (RLGY) (FANG) Upgraded; (AMZN) (STI) (MTDR) Downgraded
-
Roth Capital Comments on Ligand (LGND) Following SAGE-547 Update
-
Roth Capital Raises PT on Galena (GALE) to $8 Following Zuplenz Licensing News

